Josephus Johannes De Kimpe

This inventor holds 15 USPTO granted patents and 20 published patent applications, plus 7 CIPO patents and 13 EPO patents, primarily in Genetic Disorders. Top assignees: Biomarin Technologies B.v., Academisch Ziekenhuis Leiden, Prosensa Technologies B.v.. Active years: 2012-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Josephus Johannes De Kimpe. Retrieved from https://idiyas.com/inventor/josephus-johannes-de-kimpe

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 20)

% Patents Active = 86.7

CIPO Patents = 7 (Patent Applications = 6)

EPO Patents = 13 (Patent Applications = 16)

Average Co-Inventor Count = 3.7

ph-index = 9

Forward Citations = 350(Granted Patents)

Company Filing History:

10 out of 16

Biomarin Technologies B.v.

patents

7 out of 47

Academisch Ziekenhuis Leiden

patents

2 out of 4

Prosensa Technologies B.v.

patents

4. 1 out of 43

Academisch Ziekenhuis Leiden (h.o.d.n. Lumc)

Vico Therapeutics B.v.

patents

7. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2012-2023

Loading Chart...

Areas of Expertise:

Oligonucleotide

Duchenne Muscular Dystrophy

Exon Skipping

DNA Repeat Instability

Genetic Disorders

Muscle Disorders

Inflammatory Disorder

mRNA Treatment

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11634714 - Oligonucleotide comprising an inosine for treating DMD (2023-04-25),

2. 11427820 - Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA (2022-08-30),

3. 11274299 - Methods and means for treating DNA repeat instability associated genetic disorders (2022-03-15),

4. 11034956 - Oligonucleotide comprising an inosine for treating DMD (2021-06-15),

5. RE48468 - Means and methods for counteracting muscle disorders (2021-03-15),

6. 10689646 - Treatment of genetic disorders associated with DNA repeat instability (2020-06-23),

7. 10533171 - Oligonucleotide comprising an inosine for treating DMD (2020-01-14),

8. 10246707 - Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means (2019-04-02),

9. 9926557 - Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA (2018-03-27),

10. 9890379 - Treatment of genetic disorders associated with DNA repeat instability (2018-02-13),

11. 9528109 - Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA (2016-12-27),

12. 9243245 - Means and methods for counteracting muscle disorders (2016-01-26),

13. 9139828 - Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means (2015-09-22),

14. 8802645 - Molecule for treating an inflammatory disorder (2014-08-12),

15. 8263760 - Methods and means for treating DNA repeat instability associated genetic disorders (2012-09-11),

Title: Josephus Johannes De Kimpe: Innovator in Duchenne Muscular Dystrophy Research

Introduction

Josephus Johannes De Kimpe is a noteworthy inventor based in Utrecht, Netherlands, recognized for his contributions to the field of genetic research, particularly in the treatment of Duchenne Muscular Dystrophy (DMD). With a remarkable portfolio of 15 patents, his work is transforming therapeutic approaches to genetic disorders.

Latest Patents

De Kimpe's latest patents include groundbreaking inventions aimed at treating DMD. One of his notable inventions involves an oligonucleotide comprising an inosine, which is engineered to be complementary to sections of dystrophin pre-mRNA. This innovation is significant for its potential use in preventing or treating DMD or Becker Muscular Dystrophy (BMD).

Additionally, De Kimpe developed methods for the efficient skipping of exon 45 in DMD pre-mRNA, which can be facilitated by an antisense molecule that targets a specific sequence within the exon. This approach aims to alter the progression of Duchenne Muscular Dystrophy, showcasing his commitment to enhancing patient outcomes through innovative solutions.

Career Highlights

Josephus Johannes De Kimpe has worked with esteemed organizations such as Biomarin Technologies B.V. and Academisch Ziekenhuis Leiden. His career reflects a deep dedication to advancing medical science and improving therapeutic techniques through rigorous research and development.

Collaborations

Throughout his career, De Kimpe has collaborated with distinguished colleagues, including Gerard Johannes Platenburg and Judith Christina Theodora Van Deutekom. These partnerships have played a crucial role in driving forward his research initiatives and fostering innovation within the field.

Conclusion

In conclusion, Josephus Johannes De Kimpe stands out as a vital contributor to the realm of genetic therapies for Duchenne Muscular Dystrophy. His numerous patents and collaborative efforts emphasize the importance of innovation in addressing complex medical challenges. Through his work, De Kimpe is not only shaping the future of treatment options for DMD but also inspiring future generations of inventors in the realm of medical science.

Profile summary based on public USPTO records.